Multiple Sclerosis, Radiologically Isolated Syndrome
Conditions
Brief summary
To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis
Interventions
OTHERAnalysis of cerebrospinal fluid and serum
Analysis of biomarkers in patient biological samples
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients have given their free consent for use of their samples in research * Patients have at least 2 years of clinical and radiological follow-up data available Exclusion criterion * No follow-up of patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of GFAP in cerebrospinal fluid | Baseline | ELISA |
| Level of secreted glycoprotein in cerebrospinal fluid | Baseline | ELISA |
| Level of tumour necrosis factor receptor in cerebrospinal fluid | Baseline | ELISA |
| Level of Neurofilament in cerebrospinal fluid | Baseline | ELISA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of GFAP in serum | Baseline | ELISA |
| Level of secreted glycoprotein in serum | Baseline | ELISA |
| Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients | Baseline | Log-rank test |
| Compare prognostic value of all four markers of the high risk criteria (age below 37, male, myelitis). | Baseline | Multivariate analysis |
| Biomarker levels in CSF and serum in different patient subpopulations (Radiologically Isolated Syndrome, recurrent remittent MS, symptomatic controls, central nervous system inflammatory disease controls, non-inflammatory disease controls) | Baseline | — |
| Level of tumour necrosis factor receptor in serum | Baseline | ELISA |
| Level of Neurofilament in serum | Baseline | ELISA |
Countries
France
Outcome results
None listed